Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection

Launched by CHINESE ACADEMY OF MEDICAL SCIENCES · Aug 29, 2015

Keywords

ClinConnect Summary

HCC is the sixth most common malignancy worldwide.Selected patients with HCC are candidates for potentially curative therapy, such as hepatic resection and liver transplantation. Nevertheless,tumor recurrence is 70 % at 5 years after resection and 15-30 % after liver transplantation,leading to tumor-related death.MVI is currently one of the most critical factors predictive of HCC recurrence.There are no approved effective interventional measures to improve the outcome of this patients with MVI.The purpose of this study is to explore the validity and safety of sorafenib and TACE for MVI in H...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18-75 years of age;
• • The liver tumor has been radically resected;
• • Postoperative pathology proved to be hepatocellular carcinoma with negative margin and microvascular invasion;
• • Imaging evaluations(CT/MRI) were performed at 1 month after the resection and no area of enhancement was seen;
• • Child-Pugh A;
• • Eastern Cooperative Oncology Group(ECOG) body condition score (PS) 0-1;
• • Then patients understand and voluntarily signed a written informed consent;
• Exclusion Criteria:
• • Recurrent HCC;
• • pathology-proved multifocal HCC or HCC with satellite nodules;
• • Tumor thrombus in portal vein or inferior vena cava trunk;
• • Patients with extrahepatic metastasis found by radiologic or pathologic examination;
• • severe dysfunction of the heart, kidney, or other organs.The patients cannot tolerate TACE or sorafenib after general assessment of the situation;
• • Enrolled in other clinical study at the same time;
• • Previously treated with other antitumor treatments except the resection;
• • The researchers believe that the patient does not fit this study;
• • Pregnant or lactating women.